|
|
 |
|
Viewing report
|
|
|
|
Management of Urinary Incontinence and Overactive Bladder - A Global Overview
Datamonitor, June 2006, Pages: 195
Although there are many marketed treatments for overactive bladder, there are few available for stress urinary incontinence or interstitial cystitis. Furthermore, despite available treatments for overactive bladder, many are associated with side effects leading to poor treatment compliance. With significant unmet needs remaining in these markets, there are clear opportunities for new entrants.
Scope of this title:
- Overview of epidemiology, presentation and referral patterns, and diagnostic assessment for UUI, SUI, MUI, dry OAB, and IC
- Role and use of non-pharmacological versus pharmacological treatment for UUI, SUI, MUI, dry OAB, and IC
- Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin, solifenacin and duloxetine
- Evaluation of unmet needs and future outlook including awareness of the R&D drug pipeline
Highlights of this title:
- Drug therapy for urinary disorders has predominantly focused on the overactive bladder market - particularly urge urinary incontinence (UUI). However, as the UUI market becomes increasingly crowded, product differentiation is key. By focusing on the urgency and frequency symptoms, companies may be able to tap into an under-served market niche.
- Stress urinary incontinence (SUI) is considered the most common subtype of urinary incontinence, but poor awareness and limited treatment options have impacted presentation, diagnosis and treatment rates. The recent approval of duloxetine in the EU presents physicians with a much-needed treatment alternative, but uptake has been slow.
- Poor understanding of the underlying causes of interstitial cystitis (IC) have made diagnosis, management and development of effective drugs for this disorder difficult. With many physicians resorting to treatments that are not specifically approved for IC, experts in the field believe that this could be leading to suboptimal treatment outcomes.
Reasons to order your copy:
- Forecast product sales by understanding key aspects of epidemiology, diagnosis and treatment
- Gain a better understanding of the challenges facing current and future players in the overactive bladder and urinary incontinence market
- Identify physicians key concerns including unmet needs and the attributes that physicians believe are desirable for future treatments
Customers who bought this item also bought
Dry Overactive Bladder - A Precursor to Wet Overactive Bladder?
Urinary Incontinence and Overactive Bladder - The Perspective of the Continence Nurse in the US
Stress Urinary Incontinence - Opinion Divided on Drug Therapy
Interstitial Cystitis - Few Treatments, Poor Outcome
European Urinary Incontinence Therapeutics Markets
Mixed Urinary Incontinence - An Opportunity for Novel Drug Therapies
Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
Pipeline and Commercial Insight: Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
Kidneys and Genito-Urinary System - Overactive Bladder Drug Pipeline Report
Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs
Urinary Incontinence: Major Milestones
Trends and Developments in the European Urinary Incontinence
|
|
|
|
